Bastide to Sell Experf to Sapio to Accelerate Debt Reduction
Bastide Group has signed a purchase agreement for the sale of its subsidiary New Medical Concept, the holding company of the Experf group, which specializes in home infusion and nutrition, to Sapio Group. This cash transaction will allow the group to crystallize the value created since the acquisition of Experf in 2017 and to continue its debt reduction.
Experf, integrated into Bastide Group in 2017, recorded a turnover of approximately 18 million euros with more than 15 locations in France at that time. For the 2024-2025 fiscal year, the group operates a network of 28 agencies and generated a turnover of 42 million euros, reflecting a doubling of its activity due to the development of its territorial network and the strengthening of its teams. The sale is part of Bastide Group's asset management strategy and optimization of its business portfolio.
Financial Impact and Maintenance of 2025-2026 Objectives
This cash transaction will allow for continued debt reduction and a decrease in financial expenses. The financial leverage ratio (post IFRS 16) is expected to be slightly above 2.5x post-transaction, compared to 2.77x as of December 31, 2025. Given the expected date of deconsolidation, this sale will not have a significant impact on the published revenue for the current fiscal year (ending June 30, 2026), with the target maintained at at least 510 million euros and an operating margin around 9.0%.
Completion Conditions and Advisory Support
The completion of the transaction remains subject to customary suspensive conditions, particularly related to the information-consultation of the Social and Economic Committee. Oddo BHF acted as the exclusive financial advisor for Bastide Group, ADVANT Altana as legal counsel, while Sapio Group was advised by Goodwin Procter LLP as legal counsel and Eight Advisory for financial and tax advice. Marsh supported the due diligence in insurance matters.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Context
Period
Period: T1 2027
Key reported figures
Revenue: 124,3 millions d'euros
Quarterly revenue: 124,3 millions d'euros
Revenue growth: 7,5 %
Guidance from the release
The Group's Q1 performance confirms the strength of its business momentum and its full confidence in achieving its full-year targets
Opportunities identified
International markets showing very strong momentum with growth of nearly 20%, driven by Oxystore Italy and Intus UK performances
Diabetes business recorded growth of more than 20% with positive volume and pricing effects
Respiratory care maintained strong momentum at 10.6% growth supported by structural market growth and market share gains
Outlook / guidance
Expected revenue: 500 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.